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C BY-NC-Abstract In the present investigation, a series of 2(4-pyridyl)-5[(aryl/heteroarylamino)-1-oxoeth-
yl]thio-1,3,4-oxadiazole were synthesized using isonicotinohydrazide and substituted aryl/heteroaryl
amines using pyridine as solvent. Newly synthesized compounds were tested for their in vitro
anti-tubercular activity against Mycobacterium tuberculosis H37Rv using the BACTEC 460
radiometric system. Among the synthesized compounds, compounds 2(4-pyridyl)-5((2-nitrophenyla-
mino)-1-oxoethyl)thio-1,3,4-oxadiazole (5e), 2(4-pyridyl)-5((4-nitrophenylamino)-1-oxoethyl)thio-
1,3,4-oxadiazole (5g) and 2(4-pyridyl)-5((2-pyrrolylamino)-1-oxoethyl)thio-1,3,4-oxadiazole (5k)
produced highest efﬁcacy and exhibited >90% inhibition at a concentration of 0.0077, 0.0052
and 0.0089 lM, respectively. All the new compounds were pharmacologically evaluated for their
in vitro Antimicrobial activity.
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Tuberculosis (TB) is one of the most common infectious dis-
eases known by the mankind. About 32% of the world’s pop-
ulation is infected by Mycobacterium tuberculosis – the main
causal agent of TB. Every year, approximately 8 million of
the infected people develop active TB, and 2 million die (Gus-
tavo, 2006). The incidence of TB infection has steadily risen in
the last decade (WHO progress report, 2011); World Health
Organization estimates that about 30 million people will be in-
fected byM. tuberculosis within the next 20 years. The re-emer-
gence of TB infection has been further complicated by an
increase in the prevalence of drug-resistant TB cases. Current
control efforts are severely hampered due to M. tuberculosis
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acquired immune deﬁciency syndrome (AIDS) and the spread-
ing of multidrug-resistant strains (MDR-MTB). Problems in
the chemotherapy of tuberculosis arise when patients develop
bacterial resistance to the ﬁrst-line drugs: isoniazid (INH), rif-
ampicin (RIF), ethambutol (ETH), streptomycin (STR), and
pyrazinamide (PYR) (Kathryn et al., 2009).
The ever-increasing drug resistance, toxicity, and side ef-
fects of currently used anti-tuberculosis drugs, and the absence
of their bactericidal activity highlight the need for new, safer,
and more effective antimycobacterial compounds (Mudassar
et al., 2010). Since no effective vaccine is available, the major
strategy to combat the spreading of TB is not only chemother-
apy (Sullivan et al., 2006), but also to develop new agents with
potent sterilizing activity with short duration (Ballell et al.,
2005).
One of the most effective ﬁrst-line anti-TB drugs is INH.
Many analogs featuring the structure of INH have been syn-
thesized and tested as antimycobacterials. In a critical review
published recently, the existence of more than 3000 com-
pounds based on the INH core was reported, about 66% of
them being hydrazones (Ballell et al. 2005; Janin, 2007; Scior
and Garces-Eisele, 2006). It has also been reported that
conversion of INH to oxadiazoles produces the corresponding
5-substituted-3H-1,3,4-oxadiazol-2-thione and 3H-1,3,4,-oxa-
diazol-2-ones derivatives, which are characterized by high
activity against M. tuberculosis strain H37Rv (Wilder-Smith,
1966; Maria et al., 2005). Also oxadiazoles conform to an
important class of heterocyclic compounds with a wide range
of biological activities such as antiviral (Maria et al., 2005),
tyrosinase inhibitors (Tan et al., 2006), antimicrobial (Khan
et al., 2005; Gaonkar et al., 2006; Mojahidul et al., 2008;
Pachhamia and Parekh, 1988), cathepsin K inhibitors (Palmer
et al., 2006), fungicidal (Mojahidul et al., 2008; Li et al., 2006),
antineoplastic properties (Aboraia et al., 2006). Accordingly,
their synthesis and transformations have been a focus of inter-
est for a long time.
Herein, we report the synthesis of some 2(4-pyridyl)-5[(aryl/
heteroarylamino)-1-oxoethyl] thio-1, 3, 4-oxadiazole deriva-N
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Scheme 1tives (Scheme 1) and their in vitro antimicrobial activity and
anti tubercular activity.2. Experimental
2.1. General
All the melting points were determined with a PMP–DM scien-
tiﬁc melting point apparatus and are uncorrected. The purity
of compounds was checked by TLC (0.5 mm thickness) using
silica gel-G coated Aluminum plates (Merck) and spots were
visualized by exposing the dry plates in iodine vapors. IR spec-
tra (m max in cm1) were recorded on a Perkin Elmer spectrum
BX series FT-IR spectrometer using the KBr or Nujol tech-
nique. 1H NMR spectra were recorded on a Bruker WM
400 FT MHz NMR instrument, using CDCl3 or DMSO-d6
as solvent and TMS as internal reference (chemical shifts in
d ppm). The elemental analysis (C, H, N) of compounds was
performed at SICART, Vallabh Vidyanagar, Anand, Gujarat
(India) on Carlo Erba1108 elemental analyzer. Their results
were found to be in good agreement with the calculated values.2.2. Chemistry
The building blocks 2(4-pyridyl)-5-mercapto-1,3,4-oxadiaz-
ole(2) and 2(4-pyridyl)-5(2-chlorooacetyl)mercapto-1,3,4-oxa-
diazole(3) were prepared according to reported procedure
(Khan et al., 2004) (Scheme 1).
2.2.1. General procedure for the synthesis of 2(4-Pyridyl)-5[(2-
aryl amino)-1-oxoethyl] thio-1,3,4-Oxadiazole(5a-i)
In pyridine (30 ml.), a mixture of compound 3 (0.01 mol) and
aryl/heteroaryl amine (4a-l) (0.01 mol) was reﬂuxed for 4–5 h.
Excess of pyridine was distilled off. The resulting residue was
poured in ice-cold water to get the crude product. It was ex-
tracted with CH2Cl2 (30 · 3 ml.). After evaporation of CH2Cl2
at room temperature, the ﬁnal product was separated. The
progress of reaction was monitored by TLC using metha-
nol:toluene (10:1) as eluent.
2.2.1.1. 2(4-pyridyl)-5[(2-phenylamino)-1-oxoethyl]thio-1,3,4-
oxadiazole(5a). Yield 67%, M.p. 168–169 C. IR, m (cm1):
3425 (NH str. of 2 amine), 3076 (ArH), 1707, 1637 (C‚O
str.), 1534, 1485, 1450 (1,3,4-oxadiazole ring), 1171 (CAOAC
str.), 1053 (CAO str. of 1,3,4-oxadiazole ring), 1257.20
(CASAC str.), 1485 (C‚N str.). 1H NMR (400 MHz,
DMSO-d6), d ppm: 6.40–7.06 (m, 5H, ArH, aryl ring), 4.01
(s, 1H, NH), 4.14 (s, 2H, CH2), 7.62(d, J = 9 Hz, 2H, CH,
4-pyridyl ring), 8.64(d, J = 9Hz, 2H, CH, 4-pyridyl ring).
13C NMR (100 MHz, DMSO-d6), d ppm: 120.2–
151.7(C1AC5), 197.2(C14,C‚O), 6.1(C15, CH2), 148.9(C12),
149.6(C13), 111.5–143.5(C6AC11). Anal. Calcd for
C15H12N4O2S: C, 57.68; H, 3.87; N, 17.94; S, 10.27. Found:
C, 57.54; H, 3.76; N, 17.76; S, 10.22.
2.2.1.2. 2(4-pyridyl)-5[(2-chlorophenylamino)-1-oxoeth-
yl]thio-1,3,4-oxadiazole(5b). Yield 66%, M.p. 171–172 C.
IR, m (cm1): 3435 (NH str. of 2 amine), 3077 (ArH), 1718,
1627 (C‚O str.), 1529, 1490, 1451 (1,3,4-oxadiazole ring),
1165 (CAOAC str.), 1059 (CAO str. of 1,3,4-oxadiazole ring),
1251.20 (CASAC str.), 1487 (C‚N str.), 723 (CACl str.).
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ArH, aryl ring), 3.9 (s, 1H, NH), 4.16 (2H, CH2), 8.66(d,
J = 9 Hz, 2H, CH, 4-pyridyl ring), 7.58(d, J = 9 Hz, 2H,
CH, 4-pyridyl ring). 13C NMR (100 MHz, DMSO-d6), d ppm:
120.7–151.9(C1AC5), 187.7(C14,C‚O), 59.4,C15(CH2),
117.3(C11); 112.5–144.6(C6AC10); 148. 5149. 4(C12,C13). Anal.
Calcd for C15H11ClN4O2S: C, 51.95; H, 3.20; N, 16.16; O, 9.23;
S, 9.25. Found: C, 51.83; H, 3.29; N, 16.18; S, 9.33.
2.2.1.3. 2(4-pyridyl)-5[(3-chlorophenylamino)-1-oxoeth-
yl]thio-1,3,4-oxadiazole (5c). Yield 67%, M.p. 174–175 C.
IR, m (cm1): 3441 (NH str. of 2 amine), 3056 (ArAH),
1731, 1612 (C‚O str.), 1539, 1483, 1457 (1,3,4-oxadiazole
ring), 1170 (CAOAC str.), 1067.09 (CAO str. of oxadiazole
ring), 1238 (CASAC str.), 1490 (C‚N str.), 718 (CACl str.).
1H NMR (400 MHz, DMSO-d6), d ppm: 6.33–6.99 (m, 4H,
ArH, aryl ring), 4.19 (s, 2H,ACH2), 4.3 (s, 1H, NH), 8.62(d,
J = 9 Hz, 2H, CH, 4-pyridyl ring), 7.62(d, J = 9 Hz, 2H,
CH, 4-pyridyl ring). 13C NMR (100 MHz, DMSO-d6), d ppm:
120.3–151.7(C1AC5), 194.4(C14 C‚O), 65.6(C15,CH2),
148.1149.2(C12,C13), 112.5–144.6(C6AC9), 133.4(C10). Anal.
Calcd for C15H11ClN4O2S: C, 51.95; H, 3.20; N, 16.16; O,
9.23; S, 9.25. Found: C, 51.84; H, 3.21; N, 16.18; S, 9.37.
2.2.1.4. 2(4-pyridyl)-5[(4-chlorophenylamino)-1-oxoeth-
yl]thio-1,3,4-oxadiazole(5d). Yield 63%, M.p. 168–169 C.
IR, m (cm1): 3438 (NH str. of 2 amine), 3019 (ArAH),
1722, 1599 (C‚O str.), 1518, 1470, 1445 (1,3,4-oxadiazole
ring), 1153 (CAOAC str.), 1023 (CAO str. of oxadiazole ring),
1201 (CASAC str.), 1510 (C‚N str.), 734 (CACl str.). 1H
NMR (400 MHz, DMSO-d6), d ppm: 6.40–7.01 (m, 4H,
ArH, aryl ring), 4.18 (s, 2H, CH2), 3.8 (s, 1H, NH), 8.67(d,
J = 9 Hz, 2H, CH, 4-pyridyl ring), 7.59(d, J = 9 Hz, 2H,
CH, 4-pyridyl ring). 13C NMR (100 MHz, DMSO-d6), d ppm:
120.2–151.7(C1AC5); 187.7(C14,C‚O), 59.9(C15,CH2),
148.2149.7(C12,C13), 121.9(C9), 128.5–143.4(C6AC8),
112.9138.2(C10,C11). Anal. Calcd for C15H11ClN4O2S: C,
51.95; H, 3.20; N, 16.16; S, 9.25. Found: C, 51.89; H, 3.24;
N, 16.18; S, 9.34.
2.2.1.5. 2(4-pyridyl)-5[(2-nitrophenylamino)-1-oxoethyl]thio-
1,3,4-oxadiazole (5e). Yield 72%, M.p. 181–182 C. IR, m
(cm1): 3417 (NH str. of 2 amine), 3099 (ArAH), 1728,
1620 (C‚O str.), 1546, 1463, 1448 (1,3,4-oxadiazole ring),
1183 (CAOAC str.), 1040 (CAO str. of oxadiazole ring),
1229 (CASAC str.), 1490 (C‚N str.), 1523 (NO2 str.).
1H
NMR (400 MHz, DMSO-d6), d ppm: 6.70–7.96 (m, 4H,
ArH, aryl ring), 4.14 (s, 2H, CH2), 4.1 (s, 1H, NH), 8.63(d,
J = 9 Hz, 2H, CH, 4-pyridyl ring), 7.62(d, J = 9 Hz, 2H,
CH, 4-pyridyl ring). 13C NMR (100 MHz, DMSO-d6), d ppm:
114.4–149.8(C1AC11), 187.7(C14), 59.2(C15); 150.3149.4
(C12,C13), 161.8161.7(C14,C‚O), 55.9(C15,CH2). Anal. Calcd
for C15H11N5O4S: C, 50.42; H, 3.10; N, 19.60; S, 8.97. Found:
C, 50.32; H, 3.14; N, 19.67; S, 8.84.
2.2.1.6. 2(4-pyridyl)-5[(3-nitrophenylamino)-1-oxoethyl]thio-
1,3,4-oxadiazole (5f). Yield 70%, M.p. 183–184 C. IR, m
(cm1): 3433 (NH str. of 2 amine), 3123 (ArAH), 1715,
1624 (C‚O str.), 1521, 1451, 1428 (1,3,4-oxadiazole ring),
1172 (CAOAC str.), 1058 (CAO str. of oxadiazole ring),
1260 (CASAC str.), 1534 (C‚N str.). 1512 (NO2 str.).
1H
NMR (400 MHz, DMSO-d6), d ppm: 6.81–7.54 (m, 4H,ArH, aryl ring), 4.19 (2H,ACH2), 4.3 (1H,ANH), 8.66(d,
J = 9 Hz, 2H, CH, 4-pyridyl ring), 7.59(d, J = 9Hz, 2H,
CH, 4-pyridyl ring). 13C NMR (100 MHz, DMSO-d6), d ppm:
120.2–151.9(C1AC5); 187.4(C14,C‚O), 59.2(C15,CH2), 148.
9149.7(C12,C13), 149.2(C8); 107.4–144.9(C6AC11). Anal. Calcd
for C15H11N5O4S: C, 50.42; H, 3.10; N, 19.60; S, 8.97. Found:
C, 50.49; H, 3.01; N, 19.71; S, 8.89.
2.2.1.7. 2(4-pyridyl)-5[(4-nitrophenylamino)-1-oxoethyl]thio-
1,3,4-oxadiazole (5g). Yield 73%, M.p. 179–180 C. IR, m
(cm1): 3456 (NH str. of 2 amine), 3130 (ArAH), 1720,
1641 (C‚O str.), 1524, 1466, 1405 (1,3,4-oxadiazole ring),
1159 (CAOAC str.), 1050 (CAO str. of oxadiazole ring),
1272 (CASAC str.), 1534 (C‚N str.), 1531 (NO2 str.).
1H
NMR (400 MHz, DMSO-d6), d ppm: 6.67–7.98 (m, 4H,
ArH, aryl ring), 4.16 (s, 2H, CH2), 4.1 (s, 1H, NH), 8.64(d,
J = 9 Hz, 2H, CH, 4-pyridyl ring), 7.63(d, J = 9Hz, 2H,
CH, 4-pyridyl ring). 13C NMR (100 MHz, DMSO-d6), d ppm:
120.7–151.9(C1AC5); 187.2(C14,C‚O), 59.4(C15,CH2),
148.9149.5(C12,C13), 137.4(C9), 112.9–150.2(C6AC11). Anal.
Calcd for C15H11N5O4S: C, 50.42; H, 3.10; N, 19.60; S, 8.97.
Found: C, 50.39; H, 3.18; N, 19.72; S, 8.72.
2.2.1.8. 2(4-pyridyl)-5[(2-tolyl)-1-oxoethyl]thio-1,3,4-oxadi-
azole (5h). Yield 68%, M.p. 191–192 C. IR, m (cm1): 3452
(NH str. of 2 amine), 3031 (ArAH), 1712 (C‚O str.), 1594,
1550, 1492, 1420 (1,3,4-oxadiazole ring), 1147 (CAOAC str.),
1051 (CAO str. of oxadiazole ring), 1251.03 (CASAC str.),
1494 (C = N str.). 1H NMR (400 MHz, DMSO-d6), d ppm:
2.37 (s, 3H, CH3), 6.33–6.86 (m, 4H, ArH, aryl ring), 4.15 (s,
2H, CH2), 3.8 (s, 1H, NH), 8.67(d, J = 9 Hz, 2H, CH, 4-pyr-
idyl ring), 7.57(d, J = 9Hz, 2H, CH, 4-pyridyl ring). 13C
NMR (100 MHz, DMSO-d6), d ppm: 120.4–151.3(C1AC5),
187.3(C14,C‚O), 59.3(C15,CH2), 148.5149.0(C12,C13),
124.7(C11), 110.7–144.2(C6AC10); 11.9(C16). Anal. Calcd for
C16H14N4O2S: C, 58.88; H, 4.32; N, 17.17; S, 9.82. Found:
C, 58.75; H, 4.46; N, 17.28; S, 9.64.
2.2.1.9. 2(4-pyridyl)-5[(3-tolyl)-1-oxoethyl]thio-1,3,4-oxadi-
azole (5i). Yield 65%, M.p. 186–187 C. IR, m (cm1): 3450
(NH str. of 2 amine), 3065 (ArAH), 1708 (C = O str.),
1583, 1567, 1513, 1431 (1,3,4-oxadiazole ring), 1129 (CAOAC
str.), 1068 (CAO str. of oxadiazole ring), 1257 (CASAC str.),
1484 (C‚N str.). 1H NMR (400 MHz, DMSOAd6), d ppm:
2.34 (3H, CH3), 6.20–6.94 (m, 4H, ArH, aryl ring), 4.13 (2H,
CH2),4.1 (1H, NH), 8.66(d, J = 9Hz, 2H, CH, 4-pyridyl ring),
7.57(d, J = 9Hz, 2H, CH, 4-pyridyl ring). 13C NMR
(100 MHz, DMSO-d6), d ppm: 120.8–151.8(C1AC5);
187.7(C14,C‚O), 59.1(C15,CH2), 148.1149.2(C12,C13),
137.2(C10), 108.3–146.1(C6AC11), 21.3(C16). Anal. Calcd for
C16H14N4O2S: C, 58.88; H, 4.32; N, 17.17; S, 9.82. Found:
C, 58.73; H, 4.37; N, 17.37; S, 9.68.
2.2.1.10. 2(4-pyridyl)-5[(4-tolyl)-1-oxoethyl]thio-1,3,4-oxadi-
azole (5j). Yield 61%, M.p. 188–189 C. IR, m (cm1): 3456
(NH str. of 2 amine), 3065 (ArAH), 1710 (C‚O str.), 1573,
1556, 1522, 1443 (1,3,4-oxadiazole ring), 1123 (CAOAC str.),
1075 (CAO str. of oxadiazole ring), 1271 (CASAC str.),
1478 (C‚N str.). 1H NMR (400 MHz, DMSO-d6), d ppm:
2.36 (s, 3H, ACH3), 6.35–6.85 (m, 4H, ArH, aryl ring), 4.19
(s, 2H, CH2), 4.3 (s, 1H, NH), 8.62(d, J= 9 Hz, 2H, CH, 4-
pyridyl ring), 7.63(d, J= 9 Hz, 2H, CH, 4-pyridyl ring). 13C
Table 1 In vitro antibacterial activity of 5a-l.
Compd. R MIC (lg/mL)
Gram+ve organism Gram –ve organism
B.s S.a E.c S.t
5a H >400 – – >100
5b 2-Cl >100 >100 25 12.5
5c 3-Cl 50 25 >100 >100
5d 4-Cl 50 25 12.5 12.5
5e 2-NO2 >100 >100 >200 >200
5f 3-NO2 >400 >100 >400 >100
5g 4-NO2 – >200 >200 >400
5h 2-CH3 >100 >200 50 25
5i 3-CH3 >100 >100 >100 >100
5j 4-CH3 >200 12.5 >200 25
5k 2-C5H5N 25 12.5 12.5 25
5l 2-OH >200 >100 >100 >200
Penicillin 3.12 1.56 6.25 12.5
Streptomycin 6.25 6.25 6.25 3.12
Gram+ve Organisms, B.s.: Bacillus subtilis (MTCC 121), S.a.:
Staphylococcus aureus (MTCC 96), Gram ve Organisms, E.c.:
Escherichia coli (MTCC 443), S.p.: Salomonella paratyphi A
(MTCC 735).
104 J.P. Raval et al.NMR (100 MHz, DMSO-d6), d ppm: 120.3–151.7(C1AC5),
187.3(C14,C‚O), 59.4(C15,CH2), 148.7149.7(C12,C13),
125.1(C9), 21.4(C16), 114.6–138.5(C6AC11). Anal. Calcd for
C16H14N4O2S: C, 58.88; H, 4.32; N, 17.17; S, 9.82. Found:
C, 58.72; H, 4.53; N, 17.29; S, 9.72.
2.2.1.11. 2(4-pyridyl)-5[(2-pyrrolylamino)-1-oxoethyl]thio-
1,3,4-oxadiazole (5k). Yield 64%, M.p.201–202 C. IR, m
(cm1): 3451 (NH str. of 2 amine), 3051 (ArAH), 1716
(C‚O str.), 1576, 1580, 1526, 1423 (1,3,4-oxadiazole ring),
1143 (CAOAC str.), 1048 (CAO str. of oxadiazole ring),
1269 (CASAC str.), 1484 (C‚N str.) 1326 (NH str. of pyri-
dine). 1H NMR (400 MHz, DMSO-d6), d ppm: 6.58–8.12 (m,
4H, ArH, aryl ring), 4.15 (s, 2H, CH2), 3.7 (s, 1H, NH),
8.67(d, J = 9 Hz, 2H, CH, 4-pyridyl ring), 7.57(d, J = 9 Hz,
2H, CH, 4-pyridyl ring), 4.54–4.97 (m, 4H, CH, pyrrolyl ring),
6.7 (s, 1H, NH, pyrrolyl ring). 13C NMR (100 MHz, DMSO-
d6), d ppm: 121.6–151.2(C1AC5); 199.7(C12,C‚O),
59.8(C13,CH2), 148.2149.7(C10,C11); 18.8–75.7(C6AC9). Anal.
Calcd for C14H11N5O2S: C, 53.66; H, 3.54; N, 22.35; S,
10.23. Found: C, 53.78; H, 3.68; N, 22.54; S, 10.14.
2.2.1.12. 2(4-pyridyl)-5[(2-hydroxylphenylamino)-1-oxoeth-
yl]thio-1,3,4-oxadiazole (5l). Yield 72%, M.p.200–202 C.
IR, m (cm1): 3454 (NH str. of 2 amine), 3061 (ArAH),
1721 (C‚O str.), 1570, 1586, 1526, 1412 (1,3,4-oxadiazole
ring), 1134 (CAOAC str.), 1054 (CAO str. of oxadiazole ring),
1280 (CASAC str.), 1478 (C‚N str.). 1H NMR (400 MHz,
DMSO-d6), d ppm: 5.1 (s, 1H, OH), 6.24–6.57 (m, 4H, CH,
aryl ring), 4.19 (s, 2H,CH2), 4.3 (s, 1H, NH), 8.67(d,
J = 9 Hz, 2H, CH, 4-pyridyl ring), 7.57(d, J = 9 Hz, 2H,
CH, 4-pyridyl ring). 13C NMR (100 MHz, DMSO-d6), d ppm:
120.7–151.9(C1AC5), 187.2(C14,C‚O), 59.1(C15,CH2), 148.8,
149.9(C12,C13), 109.3–142.7(C6AC11). Anal. Calcd for
C14H11N5O2S: C, 54.87; H, 3.68; N, 17.06; S, 9.77. Found:
C, 54.70; H, 3.61; N, 17.24; S, 9. 72.
2.3. In vitro antibacterial activity
Antibacterial activity (Srinivas et al., 2005), was investigated
in vitro on gram +ve and gram ve bacteria. The standard
strains used in these tests were: Staphylococcus aureus (MTCC
96), Bacillus subtlis (MTCC 121), Escherichia coli (MTCC
443), and Salomonella paratyphi A (MTCC 735). A logarithmic
phase culture of each bacterial strain was diluted with nutrient
broth in order to obtain a density of 106 CFU mL1. Nutrient
broth (pH 6.9) and Hinton agar (pH 7.4) were purchased from
Hi-media Laboratory Pvt. Ltd. The test was performed in a
96-well microtiter plate in a ﬁnal volume of 100 ll. Test com-
pounds were dissolved in dimethyl sulfoxide (DMSO) at an ini-
tial concentration of 1000 lg mL–1 and serially diluted in the
plate using the nutrient broth. Each well was then inoculated
with the standardized bacterial suspension (106 CFU ml1)
and incubated at 37.0 C for 18–24 h. One well containing bac-
teria without sample (growth control), and one well only con-
taining broth (sterility control) were also used. After the
incubation, the growth (or its lack) of the bacteria was deter-
mined visually both in wells containing test compound and
in the control wells. The lowest concentration at which there
was no visible growth (turbidity) was taken as the MIC. In
addition, 5 lL of the suspension from each well was inoculated
in a Muller Hinton agar plate to control bacterial viability.Standard antibacterial agents such as Penicillin and Strepto-
mycin were also screened under identical conditions for com-
parison. The minimum inhibitory concentration (MIC)
values are presented in Table 1.
2.4. Antitubercular activity
The primary screening was conducted at (6.25 lg/ml) concen-
tration against M. tuberculosis H37Rv (ATCC27294) in BAC-
TEC 12B medium using the BACTEC 460 radiometric system
(Interleid, 1991; Colins and Franzblau, 1997). Compounds
demonstrating at least 90% inhibition in the primary screen
were re-examined at lower concentration (MIC) in broth mi-
cro-dilution assay with Alamar Blue. The MIC was deﬁned
as the lowest concentration inhibiting 99% of the inoculum.
Concurrent with the determination of MICs, compounds were
tested for cytotoxicity (IC50) in VERO at concentration equal
to and greater than the MIC for M. tuberculosis H37Rv after
72 h of exposure, viability is assessed on the basis of cellular
conversion of MTT into a formazan product using the Prome-
ga Cell Titer 96 Non-radioactive Cell proliferation assay. The
data of compounds are recorded in Table 2. The anti-tubercu-
lar activity was found in the range of 22–96% growth of
inhibition.
3. Results and discussion
3.1. Chemistry
Using commercially available isonicotinohydrazide (1)
new oxoethylthio-1,3,4-oxadiazole derivatives (5a-l) were
synthesized. Building blocks 2(4-pyridyl)-5-mercapto-1,3,4-
oxadiazole(2) and 2(4-pyridyl)-5(2-chlorooacetyl)mercapto-
1,3,4-oxadiazole(3), were prepared according to reported
procedure (Khan et al., 2004). Compound (3) undergoes nucle-
ophilic substitution with various aryl/heteroaryl amines (4a-l)
Table 2 Anti-tubercular activity of the synthesized compounds against M. tuberculosis H37Rv.
Compd. Primary screen (6.25 lg/mL) % inhibition Concentration (lM) Actual MIC (lg/mL) C log P*
5a >6.25 64 0.0354 – 0.4996
5b >6.25 12 0.1640 – 1.5150
5c >6.25 32 0.1706 – 1.5150
5d >6.25 28 0.1735 – 1.5150
5e >6.25 92 0.0077 6.05 0.8964
5f >6.25 86 0.0132 5.92 0.8964
5g >6.25 96 0.0052 6.00 0.8964
5h >6.25 63 0.1130 – 0.9986
5i 6.25 62 0.1138 – 0.9986
5j >6.25 64 0.1133 – 0.9986
5k >6.25 96 0.0089 5.77 0.8943
5l 6.25 69 0.1184 – 9.1673
Isoniazid >6.25 98 0.025 – 0.05 0.6680
* C log P = calculated using Chemdraw ultra software.
Synthesis and in vitro antibacterial activity of new oxoethylthio-1,3,4-oxadiazole derivatives 105in presence of pyridine as solvent to give (5a-l). The structures
of various synthesized compounds were assigned on the basis
of elemental analysis, IR, 1H & 13C NMR spectral analysis
(Fig. 1). These compounds were also screened in vitro for their
antibacterial and anti-tubercular activity.
3.2. In vitro antibacterial activity
Compounds (5b), (5h) with 2-Cl & 2-CH3 substitution respec-
tively to the phenyl nucleus exhibited moderate to good activ-
ity against gram-negative organisms and compounds (5c), (5d)
with 3-Cl & 4-Cl substitution respectively to the phenyl
nucleus exhibited moderate to good activity against gram-
positive organisms only. Compound (5j) with 4-CH3 exhibits
moderate to good activity against Staphylococcus aureus
(MTCC 96) and Salomonella paratyphi A (MTCC 735). While
the compound (5k) with 4-C5H5N exhibited remarkable anti-
bacterial activity against all tested organisms. The remaining
compounds showed poor or no activity, even at concentrations
of 100 lg/ml or 400 lg/ml.
3.3. In vitro anti-tubercular activity
All newly synthesized oxoethylthio-1,3,4-oxadiazole deriva-
tives (5a-l) were tested for their anti-mycobacterial activity
in vitro against M. tuberculosis H37Rv using the BACTEC
460 radiometric system. The results are summarized in Tables
2 with INH, a standard used for comparison. Among the new-
ly synthesized compounds, compounds (5e), (5g) and (5k) pro-
duced highest efﬁcacy and exhibited >90% inhibition at a
concentration of 0.0077, 0.0052 and 0.0089 lM. Thus, the para
substituted groups substitution derivatives displayed relatively
higher inhibitory activity in general. On the other hand with
chloro, methyl group (5b), (5c), (5d) and unsubstituted phenyl
group (5a) showed relatively low inhibitory activity againstM.
tuberculosis H37Rv. Instead (Cl) group and (CH3) group sub-O
N
N
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O
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3
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Figure 1 Numbering Pattern for 13C NMR Spectra.stitution at phenyl ring analog worsens the anti-mycobacterial
activity. All the newly synthesized compounds (5a-r) were
tested for cytotoxicity (IC50) in VERO cells at (62.5 lg/ml)
concentrations. After 72 h of exposure, viability was assessed
on the basis of cellular conversion of MTT into a formazan
product using the Promega Cell Titer 96 Non-radioactive Cell
proliferation method. All the active compounds were found to
be non-toxic.4. Conclusion
Among the newer derivatives, it is conceivable that some of the
derivatives that displayed promising anti-mycobacterial activ-
ity can be further modeled to exhibit better potency than the
standard drugs. Thus, the new synthesized oxoethylthio-
1,3,4-oxadiazole derivatives may provide valuable leads for
developing new antibacterial agents.Acknowledgments
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